Cardiac medical device maker AtriCure today announced preliminary financial results for fourth quarter and full year 2012.
Preliminary revenue for the fourth quarter of 2012 is expected to be approximately $18.4 million, about 9.5% more than fourth quarter 2011. Preliminary revenue for full year 2012 is expected to be $70.2 million, reflecting year-over-year growth of 9.1%.
West Chester-based AtriCure manufactures and markets cardiac surgical ablation systems designed to treat atrial fibrillation (AF) and systems for the exclusion of the left atrial appendage. The company brought on Mike Carrel as president and CEO AtriCure in November.
“In my first two months at AtriCure, I have spent considerable time evaluating the strategic and operational aspects of the company through in depth conversations with employees, clinical partners, customers, and shareholders,” Carrel said. ”I have found many strengths—we have truly differentiated technology, solid customer relationships, an unparalleled training program, and a talented and committed group of employees.
Read AtriCure’s full news release here.
